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Introduction
Sialic acids are typically found as terminal monosaccha-
rides of glycans carried by cell surface glycoproteins. Over
20 different sialyltransferases are known to mediate the
sialylation and generate sialic acid diversity.1,2 As a result
of their terminal position, sialic acids are key structural
determinants for a number of cell surface receptors
involved in the immune response, such as the Siglecs and
selectins (reviewed in refs 3 and 4). Sialic acid moieties
are also ligands for a diverse array of exogenous lec-
tins, from other host cells and invasive pathogens.5
He´lio J. Crespo,1 M. Guadalupe
Cabral,1 Alexandra V. Teixeira,1
Joseph T. Y. Lau,2 He´lder Trindade1
and Paula A. Videira1
1Departamento de Imunologia FCM-UNL,
Campo Ma´rtires da Pa´tria 130, Lisboa,
Portugal, and 2Department of Molecular &
Cellular Biology, Roswell Park Cancer Insti-
tute, Buffalo, NY, USA.
doi:10.1111/j.1365-2567.2009.03047.x
Received 23 July 2008; revised 2 December
2008; accepted 16 December 2008.
Correspondence: Dr P. A. Videira,
Departamento de Imunologia FCM-UNL,
Campo Ma´rtires da Pa´tria 130, 1169-056
Lisboa, Portugal.
Email: paula.videira@fcm.unl.pt
Senior author: Paula A. Videira
Summary
Sialic acids are key structural determinants and contribute to the func-
tionality of a number of immune cell receptors. Previously, we demon-
strated that differentiation of human dendritic cells (DCs) is accompanied
by an increased expression of sialylated cell surface structures, putatively
through the activity of the ST3Gal.I and ST6Gal.I sialyltransferases. Fur-
thermore, DC endocytosis was reduced upon removal of the cell surface
sialic acid residues by neuraminidase. In the present work, we evaluate
the contribution of the sialic acid modifications in DC maturation. We
demonstrate that neuraminidase-treated human DCs have increased
expression of major histocompatibility complex (MHC) and costimulatory
molecules, increased gene expression of specific cytokines and induce a
higher proliferative response of T lymphocytes. Together, the data suggest
that clearance of cell surface sialic acids contributes to the development of
a T helper type 1 proinflammatory response. This postulate is supported
by mouse models, where elevated MHC class II and increased maturation
of specific DC subsets were observed in DCs harvested from ST3Gal.I)/)
and ST6Gal.I)/) mice. Moreover, important qualitative differences, partic-
ularly in the extent of reduced endocytosis and in the peripheral distribu-
tion of DC subsets, existed between the ST3Gal.I)/) and ST6Gal.I)/)
strains. Together, the data strongly suggest not only a role of cell surface
sialic acid modifications in maturation and functionality of DCs, but
also that the sialic acid linkages created by different sialyltransferases
are functionally distinct. Consequently, with particular relevance to DC-
based therapies, cell surface sialylation, mediated by individual sialyl-
transferases, can influence the immunogenicity of DCs upon antigen
loading.
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Deficiencies in specific sialylation result in immunological
abnormalities in animal experiments, such as aberrant
T-lymphocyte counts in the mice deficient for ST3Gal.I,6
and altered B-lymphocyte proliferation in mice deficient
for ST6Gal.I.7
Dendritic cells (DCs) are special antigen-presenting cells
that uptake, process and present antigens found in periph-
eral blood and tissues to lymphocytes and regulate cellular
and humoral immune responses.8 Antigen uptake, as well
as inflammatory stimuli, induces DC maturation, enabling
DC interaction with T lymphocytes and the initiation of
adaptive immune responses.9 Maturation of DC is charac-
terized by phenotypic and physiological changes, i.e. the
antigen-uptake machinery is down-regulated10 and the
expression of surface major histocompatibilty complex
class II (MHC II), class I (MHC I) and costimulatory mole-
cules, such as CD80 and CD86, is up-regulated.11
Ultimately, the synthesis of DC-specific cytokines is chan-
ged12 contributing to the polarization towards T helper
type 1 (Th1) or type 2 (Th2),13 with the type and context
of stimuli and the consequent activation state of DC affect-
ing its Th1- or Th2-promoting effector function.13
As a result of their role in initiating the specific
immune response, monocyte-derived DCs (moDCs) are
currently used in immune adoptive vaccine protocols to
treat cancer patients.14 However under some circum-
stances (such as lack of or inappropriate maturation),
DCs can also induce and maintain antigen tolerance,15,16
a situation counterproductive to the therapeutic value of
DC therapy.
Currently, there is great interest in altering the DC
immunogenicity towards Th1-promoting cells, and subse-
quent use in immunotherapy against cancer, because
most tumour antigens are self antigens and therefore poor
immunogens. The identification of mechanisms for DC
activation is critical to more successful exploitation of the
DC modality in the prevention and treatment of cancer.
Evidence from different groups suggests that the state
of sialylation of DCs may influence their response.17,18
We have previously studied the surface sialylation of
human moDCs and we observed a significantly increased
expression of sialylated structures during the differentia-
tion of monocytes into moDCs, most probably as the
result of the activity of ST3Gal.I and ST6Gal.I sial-
yltransferases.19 In addition, we have also observed that
the removal of the sialylated structures by neuraminidase
treatment diminished the moDC capacity for endocyto-
sis,19 suggesting a triggering of DC maturation. Boog
et al.17, showed that removal of sialic acid restored spe-
cific immune responses to mice non-responder DCs,
leading to the proposal that reduction of sialic acid con-
tributed to DC activation. In the present study we analy-
sed the consequences of reduced sialylation, in human
DCs, to evaluate its contribution to the triggering of cell
maturation.
Our data demonstrated that neuraminidase treatment
results in increased expression of MHC and costimulatory
molecules, and affects some aspects of the functionality of
human DCs. Namely, neuraminidase-treated DCs show
increased gene transcription of proinflammatory and
Th1-promoting cytokines and induce greater proliferative
responses of T lymphocytes. To correlate a specific sialyla-
tion deficiency with the triggering of DC maturation, we
also analysed DCs from ST3Gal.I)/) and ST6Gal.I)/)
mice. The expression of specific maturation markers were
examined in ex vivo DCs obtained from blood, lymph
nodes and spleen. The results show an increased expres-
sion of MHC II molecules in ST6Gal.I)/) DCs, mainly in
the B220+ DC subset. The DCs differentiated in vitro
from bone marrow progenitors (BMDCs) of both defi-
cient mouse strains presented increased expression of
MHC II molecules and a reduced capacity for endocyto-
sis, when compared with wild-type (WT) mice with nor-
mal sialyltransferase expression profiles. Overall, these
data suggest a novel role for the sialylated glycans; in par-
ticular, those generated by ST3Gal.I and ST6Gal.I sial-
yltransferases, in the modulation of the DC maturation
state. Finally, we suggest that the immunogenicity of anti-
gen-loaded DCs used in cell vaccines may depend on its
sialylation content.
Materials and methods
Media and reagents
RPMI-1640 supplemented with 10% fetal calf serum from
Sigma (St Louis, MO, USA), 2 mM L-glutamine, 1% non-
essential amino acids, 1% pyruvate, 100 lg/ml penicillin/
streptomycin and 50 lM 2-mercaptoetanol, all from Gib-
co-Invitrogen (Paisley, UK) was used throughout this
study for cell culture. Human and mouse recombinant
interleukin-4 (IL-4) and granulocyte–macrophage colony-
stimulating factor (GM-CSF) were purchased from R&D
Systems (Minneapolis, MN). Neuraminidase from Clos-
tridium perfringens and collagenase D from Clostridium
histolyticum were from Roche Diagonostics (Basel, Swit-
zerland). Tetanus toxoid (TT) and mitomycin C were
purchased from Sigma. Fluorescein isothiocyanate (FITC)
-conjugated ovalbumin and carboxyfluorescein diacetate
succinimidyl ester (CFSE) were purchased from Molecular
Probes (Leiden, the Netherlands). Phytohaemagglutinin
was obtained from Fluka (Buchs, Switzerland). Anti-
human, anti-mouse and isotype control monoclonal anti-
bodies (mAbs) were purchased from BD Pharmingen
(San Diego, CA), except when otherwise stated.
Human cell isolation and generation of DCs
Human moDCs were generated from monocytes isolated,
as described previosuly19, by positive selection using
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CD14 antibody-coated magnetic beads (Miltenyi Biotech,
Bergisch Gladbach, Germany), from peripheral blood
mononuclear cells (PBMCs) of healthy volunteers pro-
vided and ethically approved by the Portuguese Blood
Institute. Monocytes were cultured in complete RPMI-
1640 medium supplemented with 1000 U/ml of recombi-
nant human IL-4 (rhIL-4) and rhGM-CSF, for 6 days, to
give rise to immature moDC.
For T-lymphocyte proliferation assays, moDCs were
generated, as described above, from monocytes isolated,
after informed consent, from PBMCs of healthy volun-
teers who had been vaccinated with TT within the previ-
ous 12 months. In these cases, the negative fractions
(CD14) PBMCs), obtained after monocyte isolation,
were maintained in culture until mixed lymphocyte cul-
tures with autologous moDCs. On day 5, moDCs were
pulsed with or without 5 lg/ml TT and, 18 hr later,
moDCs were inactivated with 005 mg/ml mitomycin C
for 30 min and washed three times with 10 ml RPMI-
1640 medium. These conditions were previously opti-
mized, by testing different parameters described in the
literature.20,21
Neuraminidase treatment
Cells were resuspended in RPMI-1640 (5 · 106/ml) and
treated with 200 mU/ml neuraminidase in serum-free
RPMI for 90 min at 37. In parallel, identical samples
were mock-treated in the same conditions with heat-
inactivated neuraminidase (20 min at 100).
Phenotypical analysis of human moDC maturation
For the analysis of the moDC maturation phenotype,
2 · 105 cells were first incubated with 01 mg/ml of
FITC-conjugated ovalbumin, in RPMI-1640 + 10% fetal
calf serum, for 1 hr, at 4 or 37. Following incubation,
moDCs were treated or mock-treated with neuraminidase
as described above. Half of the cells were reserved for
RNA extraction and real-time polymerase chain reaction
(PCR). The remaining cells were washed with FACS Flow
(BD Biosciences, Franklin Lakes, NJ) and stained with
either phycoerythrin (PE)-labelled anti-human leucocyte
antigen (HLA)-DR (L243), anti-HLA-ABC (W6/32)
(Dako Glostrup, Denmark), anti-CD80 (L307.4) or PE-
Cy5-labelled anti-CD86 (IT2.2) and analysed by flow
cytometry. All samples were analysed using a FacsCalibur
Flow cytometer and CELL QUEST (BD Biosciences) and
INFINICYT software (Cytognos, Spain).
Real-time PCR
The RNA was extracted from 1 · 106 moDCs using the
RNeasy Mini Kit (Qiagen, Chatsworth, CA) and genomic
DNA was eliminated with the RNase-Free DNase Set
(Qiagen), as described by the manufacturer. The concen-
trations of the RNA samples were determined spectro-
photometrically. The RNA was reverse transcribed with
random primers using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA).
Real-time PCR was performed in a 7500 Fast Real-
Time PCR System (Applied Biosystems) using TaqMan
Fast Universal PCR Master Mix, TaqMan probes and
primers provided by Applied Biosystems. The assay ID
provided by the manufacturer are the following: CD1a
(Hs00233332_m1); CD1b (Hs00233507_m1), CD1c
(Hs00233509_m1); IL-6 (Hs00174131_m1); IL-12a
(Hs00168405_m1); IL-1b (Hs00174097_m1); tumour
necrosis factor-a (TNF-a; Hs00174128_m1); IL-10
(Hs00174086_m1); b-actin (4352935E); glyceraldehyde
3-phosphate dehydrogenase (GAPDH; 4333764F). Each
reaction was performed in duplicate. Thermal cycling
conditions were 95 for 20 seconds followed by 40 cycles
of 95 for 3 seconds and 60 for 30 seconds.
The messenger RNA (mRNA) expression was normal-
ized using the geometric mean of the expression of the
b-actin and GAPDH genes as a reference. The relative
expression for each gene was calculated according to the
2)DDCt method described by Livak and Schmittgen.22 The
efficiency of the amplification reaction for each primer/
probe is above 95% (as determined by the manufacturer).
T-lymphocyte proliferation assays
CD14-negative PBMCs, obtained as described above, were
labelled with 556 lg/ml CFSE, for 15 min at 37, accord-
ing to the manufacturer’s instructions. The labelled cells
were then incubated with the autologous, TT-loaded moD-
Cs (treated or mock-treated with neuraminidase), in the
proportion of 8 : 1, in a 96-well round-bottom plate, for
7 days. As a positive control for T-lymphocyte prolifera-
tion, PBMCs were stimulated with 2 lg/ml phytohaema-
gglutinin, for 3 days. Evaluation of the T-lymphocyte
proliferation was performed by flow cytometry, after stain-
ing the samples with allophycocyanin-labelled anti-CD3
(clone 33-2A3) (Immunostep, Salamanca, Spain). The
number of proliferating T lymphocytes was calculated as
the percentage of CD3+ cells, with decreased CFSE
fluorescence.
Isolation and generation of mice DCs
ST3Gal.I)/) and ST6Gal.I)/) mice were obtained from the
Consortium For Functional Glycomics and originally pro-
vided by Priatel et al.6 and Hennet et al.7, respectively.
Mice were used at 10–12 weeks of age and C57BL/6 WT
animals were used as controls. All handling of animals
was previously approved by the Ethics Committee of the
Medical Sciences Faculty of Lisbon, under the supervision
of officially recognized animal handlers.
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ST3Gal.I)/), ST6Gal.I)/) and C57BL/6 mice were
killed by asphyxiation with CO2; their spleen and axillar
lymph nodes were removed and their blood was col-
lected by cardiac puncture into tubes containing ethy-
lenediaminetetraacetic acid. Cells from spleens and the
axillar lymph nodes were obtained by flushing with cul-
ture medium and mechanical disruption. Spleens were
also incubated for 20 min at 37 with collagenase D
(1 mg/ml) and submitted to red blood cell lysis (Tris–
HCl 017 M, NH4Cl 016 M) for 5 min at room temper-
ature.
The BMDC were obtained mainly as described previ-
ously.23 Briefly, the bone marrow was flushed from tibiae
and femurs with complete medium. The cell suspension
was filtered and exposed to red blood cell lysis as
described above. Bone marrow cells were cultured at
5 · 105 cells/ml on six-well plates, in culture medium
supplemented with GM-CSF and IL-4, for 6 days. The
resulting DCs were then magnetically separated by anti-
CD11c antibody-coated-magnetic beads (Miltenyi) and
confirmed by anti-CD11c staining. The average separation
efficiency was at least 85%.
Endocytosis and phenotypic analysis of BMDCs
The endocytosis assays with mouse BMDCs were per-
formed by minor modifications of the above described
moDCs endocytosis assay. Briefly, 3 · 105 cells/ml of
BMDC were incubated, for 30 min, with FITC-conjugated
ovalbumin at a final concentration of 005 mg/ml, at 4
or 37. After stopping the reaction, the cells were stained
with PE-labelled anti-MHC II (I-Ab) (AF6-1201). To
neutralize fluorescent ovalbumin linkage at the cell sur-
face, trypan blue was added and cells were washed twice
before acquisition by flow cytometry.
Flow cytometry analysis of mouse DC subsets
Blood, lymph node and splenic cells were stained with
allophycocyanin-labelled anti-CD11c (HL3), peridinin
chlorophyll protein-labelled anti-CD8a (53-6.7) or
FITC-labelled anti-B220(RA3-6B2) in combination with
anti-CD11b (NS-1), anti-CD86 (GL1) or anti-MHC II
(I-Ab) (AF6-120.1) PE-labelled mAbs. Samples were
analysed as described above. The DCs were considered
CD11c- and I-Ab-positive cells. The cut-off point for
positive staining was above the level of the control iso-
type mAbs.
Statistical analysis
Statistical comparison between two different groups was
performed using Student’s t-test (GRAPHPAD, GraphPad
Software, La Jolla, CA). Statistical significance was defined
as P < 005.
Results
Clearance of cell surface sialic acids by neuraminidase
treatment enhances cell surface expression of MHC I,
MHC II, CD80 and CD86
In our previous work, we have shown that human
moDCs, after treatment with neuraminidase, had a lower
endocytosis capacity (only 75% uptake of ovalbumin).19
A possible explanation for this observation is that neur-
aminidase treatment triggered DC maturation, a process
known to be accompanied by diminished antigen uptake.
DC activation was unlikely to be the result of heat stable
factors in the neuraminidase preparation, such as bacterial
endotoxins, because control DCs treated in parallel with
heat-inactivated neuraminidase did not show decreased
endocytosis. To assess maturation status of the DCs after
neuraminidase treatment, we have analysed, by flow
cytometry, the expression of MHC I and MHC II and the
costimulatory molecules, CD80 and CD86, by moDCs
during endocytosis and when treated with neuraminidase.
The efficiency of the neuraminidase treatment was evalu-
ated by appropriate lectin binding assays as described
elsewhere19 (data not shown).
At the end of endocytosis, the expression level of MHC
I, MHC II, CD80 and CD86 molecules was significantly
higher in the moDCs treated with neuraminidase com-
pared with mock-treated cells (Fig. 1). To further investi-
gate whether this increased expression was mainly the
result of the neuraminidase treatment itself, we have also
performed control assays with moDCs which had not
undergone endocytosis (assays performed at 4). Accord-
ing to our results, the expression level of these markers
was also significantly elevated in the cells treated with
neuraminidase, although, except for MHC I, with less
extent (Fig. 1). Control assays with the moDCs incubated
in the absence of the endocytic agent, were comparable to
the assays carried out at 4 in the presence of the agent
(data not shown). The neuraminidase treatment causes a
significant increase of MHC I and MHC II expression in
moDCs, as well as the expression of costimulatory mole-
cules, CD80 and CD86, and this is even more eminent
when followed by endocytosis.
Besides MHC molecules, human DCs prominently
express other antigen-presenting molecules, the CD1 fam-
ily (CD1a, -b and -c) that mediate the presentation of
lipid and glycolipid antigens to T lymphocytes.24 The traf-
ficking of such molecules to the plasma membrane is gen-
erally independent of the DC maturation stage,25 except
in the case of strict stimulus.26,27 In the case of neuramin-
idase treatment of moDCs, we have addressed, in parallel,
the CD1a, CD1b and CD1c gene expression, but no signif-
icant differences were found (data not shown), suggesting
that the neuraminidase treatment does not alter the
expression of CD1 on the cell surface in moDCs.
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Altered expression of cytokines in neuraminidase-
treated DCs
To investigate the functional consequence of the exposure
of human moDCs to neuraminidase, the expression of
IL-6, IL-12a, IL-1b, TNF-a and IL-10 mRNAs were analy-
sed by quantitative real-time PCR. Although there was
some sample-to-sample variation, at the end of endo-
cytosis, all neuraminidase-treated moDC samples had
increased levels of IL-6 (around 2 to 50-fold) compared
with the corresponding mock-treated moDCs (Fig. 2).
The mRNAs for IL-12a, IL-1b and TNF-a were also aug-
mented by the neuraminidase treatment in the majority
of the samples, although in one out of five samples this
increase was almost insignificant (Fig. 2). Regarding the
IL-10 expression, even though a number of moDC sam-
ples presented ± twofold increased expression, after
endocytosis and neuraminidase treatment, two out of five
samples showed a slight IL-10 down-regulation (Fig. 2).
As above, we also investigated the effect of neuraminidase
itself, by analysing the expression of these cytokines in
the moDCs which had not undergone endocytosis. Our
results showed that the neuraminidase treatment per se
led to a similar increased expression of IL-12a and IL-6
(Fig. 2). For the IL-10, IL-1b and TNF-a, there was an
up-regulation slightly higher than the neuraminidase-
treated moDCs which had undergone endocytosis
(Fig. 2). Therefore, removing the sialic acid in moDCs led
to an increased expression of IL-6, IL-1b, IL-12a and
TNF-a genes. However, the range of up-regulation
seemed to depend upon the individual donor and to be
slightly lessened during endocytosis.
Increased T-lymphocyte priming induced by
neuraminidase-treated human DCs
To further investigate the functional effect of neuramini-
dase treatment on human DCs, we evaluated the ability of
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Figure 1. Increased expression of major histocompatibility complex
class II (MHC II), class I MHC I, CD80, CD86 in human mono-
cyte-derived dentritic cells (moDCs) after neuraminidase treatment.
Neuraminidase treated (T) or mock-treated (i.e. inactivated neur-
aminidase) (MT) moDCs were pulsed with the endocytic agent oval-
bumin (005 mg/ml) and incubated for 1 hr at 37 or 4 (control).
After the endocytosis assay, the expression of MHC II (HLA DR),
MHC I (HLA ABC) and the costimulatory molecules CD80 and
CD86 were evaluated by flow cytometry. The results are the mean
fluorescence intensity (MFI) of at least three individual experiments
± SEM. Significantly different values (*P < 005 or **P < 001 paired
Student’s t-test) were observed for all the maturation markers
employed, comparing neuraminidase-treated with mock-treated
human moDCs, either in cells that had internalized ovalbumin (assay
at 37) or in the control cells (assay at 4).
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Figure 2. Expression of cytokines is altered in neuraminidase-treated
human monocyte-derived dendritic cells (moDCs). Neuraminidase
treated and mock-treated (i.e. inactivated neuraminidase) moDCs
were pulsed with ovalbumin, as described in the Materials and meth-
ods. After endocytosis, total RNA was used to generate complemen-
tary DNA that was analysed by real-time polymerase chain reaction.
Boxes represent minimum and maximum of the mean relative
expression, RQ, (± SEM) of interleukin-6 (IL 6), IL-12a, IL-1b,
tumour necrosis factor-a (TNF-a) and IL-10 genes. The results
(median with interquartile range) represent the expression of a given
gene in five different neuraminidase-treated moDCs compared with
the expression in the respective mock-treated moDCs. Values above
or below one indicate, respectively, over-expression or down-regula-
tion of a specific gene after neuraminidase treatment of moDCs,
either in cells that have internalized ovalbumin (assay at 37) or in
the control cells (assay at 4).
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either neuraminidase-treated or mock-treated moDC to
induce autologous T-lymphocyte proliferation. We have
performed mixed lymphocyte cultures with moDCs loaded
with TT, treated or mock-treated with neuraminidase, and
autologous CFSE-labelled T lymphocytes. According to
our results, the number of proliferating T lymphocytes is
significantly increased when antigen-loaded moDCs lose
their surface sialic acid (Fig. 3), as the mean value for
mixed lymphocyte cultures with moDCs loaded with TT,
treated or mock-treated with neuraminidase were 51% and
39% of CD3+ cells, respectively (P = 003). It should be
noted that the immunogenicity of ovalbumin-pulsed DCs
and TT-pulsed DCs may not be the same. Nevertheless, we
chose TT as antigen and not ovalbumin because of the spe-
cific need for antigen-specific human lymphocyte respond-
ers for the mixed lymphocyte culture.
DCs ex vivo from ST6Gal.I)/) mice show an
augmented cell surface expression of MHC II
In our previous work, we studied the sialyltransferases
involved in human moDC sialylation and highlighted the
significant contribution of ST3Gal.I and ST6Gal.I.19
Having observed that neuraminidase treatment induced
DC maturation we wished to further inspect the type of
sialylation, whose shortage was involved in this process, by
focusing on ST3Gal.I-deficient and ST6Gal.I-deficient DCs.
Therefore, the following question was whether ex vivo DCs
from mice deficient in one of these two sialyltransferases
presented a more mature phenotype. To address this ques-
tion we analysed the expression of MHC II and CD86 in
DCs present in their blood, lymph nodes and spleens.
The MHC II expression was higher in ST6Gal.I)/) DCs
when compared with WT mice, but no apparent differ-
ences were observed regarding CD86 expression (Table 1).
ST3Gal.I-deficient mice presented insignificant variation
of the MHC II and CD86 expression (Table 1).
To determine whether the increased expression of MHC
II in ST6Gal.I)/) DCs could be linked to one particular DC
subset, we focused our analysis on the lymphoid, plasmacy-
toid and conventional DC subsets, based on the DC expres-
sion of CD8a, B220 and CD11b markers, respectively
(Table 1). When examining each of these subsets for the
expression of MHC II and CD86, we noted that the
increased MHC II expression, detected in the total
ST6Gal.I)/) DCs, was mainly present in the plamacytoid
(B220+ ) DC subset (Table 1). These results suggest that
the more mature phenotype found in DCs from ST6Gal.I)/)
mice, was mainly related to the plasmacytoid DC subset.
Surprisingly, when we studied the distribution of lym-
phoid, plasmacytoid and conventional DC subsets, we
found differences in the ST3Gal.I-deficient mice, which
presented not only an increased percentage of total DCs,
but also a significant inferior percentage of CD8a+ DCs
and, conversely, increased number of B220+ DCs in the
three analysed sources (Table 2). The surface expression
of each subset marker was also evaluated based on the
overall intensity values, but no significant differences were
found (data not shown).
ST3Gal.I)/) and ST6Gal.I)/) BMDCs present lower
endocytosis capacity and increased cell surface
expression of MHC II
Since we demonstrated that at least ex vivo ST6Gal.I)/)
DCs presented increased expression of MHC II, we then
asked whether ST6Gal.I)/) or ST3Gal.I)/) DCs had
impaired endocytic capacity. To answer this, we chose
DCs differentiated in vitro from bone marrow, because
the in vitro generation of DCs from their precursors pro-
duces a percentage of DCs much higher than those
obtained by isolation from ex vivo sources.
We performed FITC-conjugated ovalbumin endocytosis
assays with ST3Gal.I)/) and ST6Gal.I)/) BMDCs. For
comparison similar assays with WT BMDCs were always
run in parallel. The percentage of BMDCs that endocyto-
sed ovalbumin was roughly identical to that of WT
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Figure 3. Increased T-lymphocyte proliferation in mixed leucocyte
reactions with neuraminidase-treated dendritic cells (DCs). Human
monocyte-derived DCs (moDCs) were stimulated with tetanus toxoid
(TT; 5 lg/ml), inactivated with mitomycin C and treated [T DC(TT)]
or mock-treated (i.e. inactivated neuraminidase) [MT DC(TT)] with
neuraminidase, as described in the Materials and methods. Control
assays with unstimulated moDCs, treated (T DC) or mock-treated
(MT DC) with neuraminidase, were also performed in parallel. The
moDCs were then cultured with autologous, carboxyfluorescein diac-
etate succinimidyl ester (CFSE)-labelled CD14) peripheral blood
mononuclear cells (PBMCs; 1 : 8 ratio), for 7 days. As a control,
CD14) PBMCs were cultured alone, in the absence or presence of
phytohaemagglutinin. Cells were stained with allophycocyanin-
labelled anti-CD3 and analysed by flow cytometry. Graph represents
the percentage of proliferating T lymphocytes, of five individual
experiments ± SEM, estimated by the percentage of CFSE-diluted,
CD3+ cells. Significantly different values were observed for the per-
centage of T-lymphocyte proliferation induced by T DC(TT)
(*P < 005 paired Student’s t-test), when compared with the one
induced by MT DC(TT).
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BMDCs (± 62%). However, the fluorescence intensity of
FITC-labelled ovalbumin was reduced in BMDCs from
ST3Gal.I)/) and ST6Gal.I)/) mice [61% (P = 00078) and
76% of fluorescence intensity relative to WT, respectively]
(Fig. 4). These observations demonstrate that ST3Gal.I)/)
and, to a lesser extent, ST6Gal.I)/) BMDCs endocytose
less ovalbumin than WT BMDCs.
We also monitored the expression of MHC II in
ST3Gal.I)/) and ST6Gal.I)/) BMDCs after undergoing
endocytosis. As expected from the ex vivo DC analysis,
ST6Gal.I)/) BMDCs showed a higher expression of MHC
II than WT (Fig. 5). Unexpectedly, ST3Gal.I)/) BMDCs
showed a significant and even higher expression of MHC
II (Fig. 5). To investigate whether the increased MHC II
expression was exclusively derived from the endocytosis
or if it was present, originally, in the ST6Gal.I)/) and
ST3Gal.I)/) BMDCs, we have analysed the MHC II
expression in the control BMDCs which had not under-
gone endocytosis. Although not statistically significant,
the intensity of MHC II fluorescence was also higher in
both control ST6Gal.I)/) and ST3Gal.I)/) BMDCs than
control WT BMDCs (Fig. 5).
Table 1. Expression of major histocompatibil-
ity complex class II and CD86 in ST3Gal.I)/)
and ST6Gal.I)/) mouse dendritic cells
compared with wild-type control
N MHC II1 MHC II (B220+)2 CD861
Blood WT 8 1570 ± 407 1173 ± 206 2278 ± 055
ST3Gal.I)/) 6 2360 ± 595 1660 ± 602 2019 ± 179
ST6Gal.I)/) 10 2804 ± 379
*P = 0046
2722 ± 269
***P = 00005
2655 ± 201
Spleen WT 6 5759 ± 614 7848 ± 940 6655 ± 537
ST3Gal.I)/) 7 5540 ± 1405 6542 ± 925 6565 ± 523
ST6Gal.I)/) 11 9031 ± 910
**P = 0009
1047 ± 938 6275 ± 728
Lymph nodes WT 7 9756 ± 1058 8643 ± 153 2094 ± 476
ST3Gal.I)/) 6 1465 ± 3668 1197 ± 171 1980 ± 144
ST6Gal.I)/) 9 1498 ± 745
**P = 0007
1810 ± 177
**P = 0003
2450 ± 445
DCs, dendritic cells; MHC II, major histocompatibility complex class II; WT, wild-type.
DCs were considered CD11c and MHC II positive cells.
N indicates the number of mice used for each determination.
Values are the mean ± SEM of mean fluorescence intensity (MFI).
1Values are related to total DCs.
2Values related to plasmacytoid (B220+) DCs.
Table 2. Distribution of dendritic cell subsets in ST3Gal.I)/) and ST6Gal.I)/) mice compared with wild-type control mice
N % DCs1
% Lymphoid DCs
(CD8a+)2
% Plasmacytoid DCs
(B220+)2
% Conventional DCs
(CD11b+)2
Blood WT 8 0938 ± 008 4400 ± 088 2394 ± 216 7353 ± 079
ST3Gal.I)/) 6 1208 ± 009
*P = 0044
07183 ± 032
**P = 0002
4303 ± 362
**P = 0002
8500 ± 226
ST6Gal.I)/) 10 0797 ± 006 4435 ± 051 1798 ± 120 5535 ± 069
Spleen WT 6 6426 ± 089 1112 ± 109 2519 ± 213 2565 ± 494
ST3Gal.I)/) 7 1182 ± 104
**P = 0004
7300 ± 130
*P = 0048
4056 ± 556
*P = 0048
3644 ± 228
ST6Gal.I)/) 11 5074 ± 072 8071 ± 089 3210 ± 152
*P = 0025
3013 ± 366
Lymph nodes WT 7 3042 ± 047 1019 ± 161 3579 ± 345 2818 ± 682
ST3Gal.I)/) 6 7220 ± 044
***P = 00002
3720 ± 181
*P = 0032
5480 ± 510
*P = 0015
4209 ± 665
ST6Gal.I)/) 9 3690 ± 075 9929 ± 198 4111 ± 197 3416 ± 624
DCs, dendritic cells; MHC II, major histocompatibility complex class II; WT, wild-type.
DCs were considered CD11c and MHC II positive cells.
N indicates the number of mice used for each determination.
1Percentage related to total leucocytes.
2Percentage related to total DCs.
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Considering the strikingly elevated MHC II expression
following endocytosis, we decided to examine this parame-
ter in detail. In particular, we wished to address whether
the increased intensity of MHC II was applied to all the
BMDCs or to a particular subpopulation. After endocyto-
sis, either WT, ST3Gal.I)/) or ST6Gal.I)/) BMDCs pre-
sented two distinguishable BMDC subpopulations
based on the mean fluorescence intensity of MHC II (MHC
IImedium and MHC IIhigh) (Fig. 5). When gating both
subpopulations and comparing the intensity of MHC II
fluorescence, the MHC IImedium subpopulation was approx-
imately identical, in the three analysed BMDCs. However,
the MHC IIhigh population of both ST6Gal.I)/) and
ST3Gal.I)/) BMDCs presented a slightly increased intensity
of MHC II fluorescence (Fig. 5). The percentage of MHC
IIhigh BMDCs compared to the MHC IImedium subpopula-
tion was about 10% and 5% higher in ST6Gal.I)/) and
ST3Gal.I)/) BMDCs, than in WT BMDCs, respectively, but0
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Figure 4. Decreased endocytic ability of ST3Gal.I)/) and ST6Gal.I)/)
bone marrow-derived dendritic cells (BMDCs). The ST3Gal.I)/) or
ST6Gal.I)/) BMDCs were incubated, for 30 min, with 005 mg/ml
fluorescein isothiocyanate-conjugated ovalbumin, as described in the
Materials and methods. Control assays were performed in parallel
with wild-type (WT) BMDCs. The mean fluorescence intensity
(MFI) values obtained at 4 were subtracted from the 37 values.
The results are expressed as the ratio of the MFI ± SEM of
ST3Gal.I)/) BMDCs (six mice) or ST6Gal.I)/) BMDCs (seven mice)
related to WT BMDC. Significantly different values were observed
for the endocytic capacity of ST3Gal.I)/) BMDC (**P < 001).
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Figure 5. Major histocompatibility complex (MHC) expression is
increased in ST3Gal.I)/) and ST6Gal.I)/) bone marrow-derived den-
dritic cells (BMDCs). The MHC II expression of ST3Gal.I)/) (ST)
and ST6Gal.I)/) (SG) BMDCs was analysed by staining with phycoer-
ythrin-conjugated anti I-Ab, after exposure to fluorescein isothiocya-
nate-conjugated ovalbumin and incubation at 37 or 4, as described
in the Materials and methods. Control assays were performed in par-
allel with wild-type (WT) BMDCs. (a) The results are expressed as
the mean fluorescence intensity (MFI) ± SEM of ST3Gal.I)/) BMDCs
(six mice) and ST6Gal.I)/) BMDCs (seven mice). Significantly differ-
ent values, related to WT BMDC, were observed at 37, for the
ST3Gal.I)/) BMDCs (*P < 005). (b) Dot-plot showing that, after
endocytosis (at 37), BMDCs express different levels of MHC II,
defining a MHC IImedium and a MHC IIhigh subpopulation. The data
shown correspond to analysis of one representative population of
BMDCs (either from WT, ST3Gal.I)/) or ST6Gal.I)/) mice) acquired
by flow cytometry. (c) MHC IImedium subpopulations of ST3Gal.I)/)
and ST6Gal.I)/) BMDCs are no different from WT BMDCs, while
MHC IIhigh subpopulations showed increased MHC II expression.
The results are the means ± SEM of the MFI for MHC II for the
MHC IImedium and MHC IIhigh subpopulations, gated as described
above. The left axis corresponds to the MHC IImedium subpopulation
and the right axis corresponds to the MHC IIhigh population.
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the differences were not statistically significant (data not
shown). Accordingly, the fluorescence intensity of FITC-
labelled ovalbumin of the MHC IImedium subpopulation
was approximately identical, in the three analysed BMDCs,
whereas the MHC IIhigh population of both ST3Gal.I)/)
and ST6Gal.I)/) BMDCs presented a decreased intensity
[49% (P = 00094) and 78% of fluorescence intensity rela-
tive to WT, respectively] (data not shown).
Collectively, these data indicate that BMDCs deficient
for ST6Gal.I or ST3Gal.I, upon endocytosis, show an aug-
mented number of fully mature BMDCs subpopulation
with decreased endocytosis capacity.
Discussion
With the recent progress of glycobiology it is becoming evi-
dent that sialic acid is relevant to the immune responses
and the evaluation of sialylation-modification at the leuco-
cyte surface contributes to a better understanding of the
immune functions. We have previously demonstrated that
the expression of surface sialylated structures was modu-
lated during moDC differentiation and maturation, and we
suggested that changes in sialylation are related to specific
DC functions.19 Nevertheless, because of the characteristic
complexity of DCs, the identification of the specific nature
and role of these structures is still difficult to predict.
Here, we show that the sialylation shortage, generated by
neuraminidase treatment, induces an increased expression
of MHC molecules and costimulatory molecules at the cell
surface of human moDCs. This increase is considerably
higher than that induced solely by the uptake of ovalbumin
(Fig. 1) or other endocytic agents, such as lucifer yellow
and dextran (data not shown). Additionally, according to
our experiments investigating the functional consequences
of sialic acid loss in DCs, neuraminidase treatment alters
the gene expression of specific cytokines and increases the
ability of DCs to prime T lymphocytes. Notably, sialic acid
shortage leads to an up-regulation of IL-1a, IL-6 and TNF-
a proinflammatory cytokines,28,29 and of IL-12, which
drives Th1 lymphocyte differentiation and the cell-medi-
ated immune response.30 In contrast, the expression of IL-
10, which plays a major role inducing tolerance in naı¨ve T
lymphocytes31 and in biasing their development into Th2
lymphocytes,32 remained basically unchanged. Increased
expression of signals, such as antigen presentation and co-
stimulatory molecules and IL-12, driving the development
of naive precursors into Th1 lymphocytes33 are key deter-
minants for DC immunogenicity. To evaluate the cytokine
profile, the expression of mRNA, but not of protein, was
analysed and it is relevant to note that a discrepancy
between mRNA and protein expression is possible. Not-
withstanding, our strategy is well suited to elucidate the
Th1- or Th2-skewed DC activation profile. Our results
suggest that neuraminidase creates an overall proinflam-
matory effect on moDCs, increasing their immunogenicity.
The idea of using neuraminidase treatment to alter DC
immunogenicity, that is to say the activation towards Th1,
needs further clarification. Neuraminidase treatment
removes non-specifically a-2,3-linked and a-2,6-linked sia-
lic acid from all cell surface sialylated constituents. Our
current data cannot predict the precise sialylated cell sur-
face structure that, upon desialylation, leads to Th1-skewed
DC activation. To obtain a better insight, we studied DCs
that were deficient for ST3Gal.I and ST6Gal.I, because
these two sialyltransferases have a good correlation between
their mRNA expression levels and the differentiation and
maturation process of human DCs and are probably the
most relevant for moDCs sialylation.19 Absence of the sialic
acid linkages specified by these sialyltransferases may both
lead to Th1-skewed DC activation. In addition, the data
derived from these mouse models with ST6Gal.I or
ST3Gal.I deficiencies suggest that the overall extent of cell
surface sialylation, and not of specific sialylated glycopro-
tein entities, may be the important contributing factor. On
the other hand, it is important to note that differences in
DC maturation and distribution were noted between
ST6Gal.I-deficient compared to ST3Gal.I-deficient and WT
animals (see Table 2). These differences may indicate func-
tional specializations for sialic acid linkages specified by the
two sialyltransferases, which, in their turn, may be depen-
dent on the presence of several cell surface molecules.
Indeed, human moDCs express several receptors, such as
Siglecs, that recognize sialic-acid-containing glycans, and
may have preferences for either the Sia(a2,3) linked to
Gal(b1,3)GalNAc or the Sia(a2,6) to Gal(b1,4)GlcNAc
structures synthesized by ST3Gal.I or ST6Gal.I, respec-
tively.34 Siglecs have the potential to interact not only
in trans with sialylated ligands found in other cells, but also
in cis with ligands found at the same cell surface.34 The
physiological functions of the majority of Siglecs are still
unknown. However, because they present immunoreceptor
tyrosine-based inhibitory motifs, they are expected to have
a major role in controlling immunity. Furthermore, addi-
tional glycan-recognizing receptors exist, and removal of
the sialic acid residues normally residing as the outermost
residue of glycans may uncover ligands for other immuno-
logically relevant carbohydrate-binding molecules such as
galectins. Some members of this family of lectins that rec-
ognize b-galactosyl-containing glycoconjugates, have been
implicated in both innate and adaptive immune
responses.35 So far it is known that Gal-3 expression in
DCs is pivotal to control the magnitude of T-lymphocyte
priming36 but the biological functions of the galectins
expressed by DCs are probably complex and are not well
understood. In this scenario, it is difficult to anticipate the
extent of molecules and mechanisms that are engaged when
DCs are treated with neuraminidase.
One point that should be addressed is the fact that the
observed DC maturation could be the result of the engage-
ment of the innate receptors because the neuraminidase,
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used throughout this study, was of bacterial origin and
could be contaminated with microbial products, particu-
larly endotoxins. Nevertheless, to rule out that possibility,
control assays were performed with a neuraminidase inacti-
vated by heat which should not destroy the endotoxins.
Considering the fact that differential sialylation can
influence the accessibility of MHC epitopes to antibodies
that recognize them,17,37 it would be possible that the
increased antibody binding to MHC molecules that is
observed in neuraminidase-treated DCs, was the result of
an enhanced antibody affinity rather than of augmenta-
tion of the number of binding sites of such molecules.
However, it should be noted that the increased immuno-
genicity of neuraminidase-treated DCs is confirmed not
only by the increased binding of MHC antibodies, as
shown by flow cytometry, but also by the transcription of
specific cytokines and by proliferation assays in mixed
lymphocyte cultures. In addition, qualitative differences in
the extent of antibody binding to MHC II molecules were
also observed among ST6Gal.I)/) and ST3Gal.I)/) DC
subsets, corroborating the idea that clearance of cell sur-
face sialic acids is indeed involved in an elevated expres-
sion of MHC II at the cell surface.
There is evidence correlating reduced sialylated struc-
tures with the activation of other leucocytes such as neu-
trophils and T lymphocytes.38,39 In the case of DCs, there
is one report describing how murine DCs treated with
neuraminidase induced specific T-lymphocyte responses
more efficiently.17 Interestingly, some sialyltransferases,
like ST6Gal.I, are known to be down-regulated after DC
maturation,18,19 suggesting that maturation, on its own,
leads to the reduction of specific sialylation.
Lymphocytes and neutrophils, from ST3Gal.I)/) and
ST6Gal.I)/) mice have been the object of several stud-
ies,6,7,40 but, as far as we know this is the first reported
characterization of their DCs. Therefore we initially stud-
ied the distribution of lymphoid, plasmacytoid and con-
ventional DC subsets in blood, lymph nodes and spleen,
based on the expression of specific markers. We have
found that ST3Gal.I-deficient mice presented a signifi-
cantly lower percentage of CD8a+ DCs and, conversely,
increased number of B220+ DCs in the periphery
(Table. 1). It is relevant to note that ST3Gal.I)/) lympho-
cytes have been described as having a similar CD8/B220
disproportion and the dramatic defect for CD8+ T lym-
phocytes in ST3Gal.I)/) mice has been relatively well doc-
umented.6 The observed alteration in the DC population,
suggests a higher content of plasmacytoid (B220+) DCs
and may be related to the fact that both CD8 and B220
molecules are the substrate of ST3Gal.I.6 However, further
analysis is required to validate the relationship of
ST3Gal.I expression and plasmacytoid DC abundance.
Our findings strongly suggest that sialic acid linkages
mediated by different sialyltransferases are functionally
distinct in DCs and have roles in DC maturation. Sialic
acid deficiency, either in ST3Gal.I)/) and ST6Gal.I)/)
BMDCs or in human neuraminidase treated moDCs, trig-
gers DC maturation. In contrast to classical maturation
stimuli,10 desialylation-triggered maturation does not dra-
matically abrogate endocytosis, and human or mouse
DCs with reduced sialic acid retain around 70% of their
endocytic capacity. In addition, the MHC II expression of
desialylated DCs is intensified upon antigen loading,
which accords with the increased capacity to induce
T-lymphocyte proliferation.
Further functional studies are still required to under-
stand the competence and immune modulatory capacities
of desialylated DCs. Nevertheless, because surface sialyla-
tion influences the immunogenicity of DCs upon antigen
loading, our findings should have a particular relevance
to DC-based therapies and they propose that sialylation is
an issue to be considered when refining the immunologi-
cal parameters of vaccination with DCs.
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